65 related articles for article (PubMed ID: 31133053)
1. Point-of-sale marketing of heated tobacco products in Israel: cause for concern.
Halpern-Felsher B
Isr J Health Policy Res; 2019 May; 8(1):47. PubMed ID: 31133053
[TBL] [Abstract][Full Text] [Related]
2. IQOS point-of-sale marketing: a comparison between Arab and Jewish neighborhoods in Israel.
Khayat A; Levine H; Berg CJ; Abroms LC; Duan Z; Wang Y; LoParco CR; Elbaz D; Cui Y; Bar-Zeev Y
Res Sq; 2024 Mar; ():. PubMed ID: 38464035
[TBL] [Abstract][Full Text] [Related]
3. Heated tobacco products likely appeal to adolescents and young adults.
McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
[TBL] [Abstract][Full Text] [Related]
4. PMI's IQOS and cigarette ads in Israeli media: a content analysis across regulatory periods and target population subgroups.
Khayat A; Berg CJ; Levine H; Rodnay M; Abroms L; Romm KF; Duan Z; Bar-Zeev Y
Tob Control; 2024 Mar; 33(e1):e54-e61. PubMed ID: 36418166
[TBL] [Abstract][Full Text] [Related]
5. Unboxed: US Young Adult Tobacco Users' Responses to a New Heated Tobacco Product.
Kim M; Watkins SL; Koester KA; Mock J; Kim HC; Olson S; Harvanko AM; Ling PM
Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33153143
[TBL] [Abstract][Full Text] [Related]
6. Low compliance and proliferation of IQOS purchase cues at points-of-sale: a comparative study before and after Israel's display ban.
Bar-Zeev Y; Berg CJ; Khayat A; Abroms LC; Wang Y; Duan Z; LoParco CR; Cui Y; Elbaz D; Levine H
Tob Control; 2024 Jun; ():. PubMed ID: 38862232
[TBL] [Abstract][Full Text] [Related]
7. Heated tobacco product marketing: a mixed-methods study examining exposure and perceptions among US and Israeli adults.
Cui Y; Bar-Zeev Y; Levine H; LoParco CR; Duan Z; Wang Y; Abroms LC; Khayat A; Berg CJ
Health Educ Res; 2024 May; ():. PubMed ID: 38739472
[TBL] [Abstract][Full Text] [Related]
8. IQOS Marketing Strategies and Expenditures in the United States From Market Entrance in 2019 to Withdrawal in 2021.
Duan Z; Levine H; Romm KF; Bar-Zeev Y; Abroms LC; Griffith L; Wang Y; Khayat A; Cui Y; Berg CJ
Nicotine Tob Res; 2023 Sep; 25(11):1798-1803. PubMed ID: 37338204
[TBL] [Abstract][Full Text] [Related]
9. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
[TBL] [Abstract][Full Text] [Related]
10. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes.
Glantz SA
Tob Control; 2018 Nov; 27(Suppl 1):s9-s12. PubMed ID: 30131374
[TBL] [Abstract][Full Text] [Related]
11. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
Berg CJ; Bar-Zeev Y; Levine H
Sage Open; 2020; 10(1):. PubMed ID: 32719733
[TBL] [Abstract][Full Text] [Related]
12. IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.
Khayat A; Levine H; Berg CJ; Shauly-Aharonov M; Manor O; Abroms L; Romm KF; Wysota CN; Bar-Zeev Y
Tob Control; 2024 Mar; 33(e1):e3-e10. PubMed ID: 36368887
[TBL] [Abstract][Full Text] [Related]
13. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
Robichaud MO; Puryear T; Cohen JE; Kennedy RD
Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry in the lungs of α-particles (
Desorgher L; Berthet A; Rossier J; Bochud F; Froidevaux P
J Environ Radioact; 2023 Jul; 263():107178. PubMed ID: 37060833
[TBL] [Abstract][Full Text] [Related]
15. Potential Harm of IQOS Smoke to Rat Liver.
Granata S; Canistro D; Vivarelli F; Morosini C; Rullo L; Mercatante D; Rodriguez-Estrada MT; Baracca A; Sgarbi G; Solaini G; Ghini S; Fagiolino I; Sangiorgi S; Paolini M
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569836
[TBL] [Abstract][Full Text] [Related]
16. Young Adult Correlates of IQOS Curiosity, Interest, and Likelihood of Use.
Phan L; Strasser AA; Johnson AC; Villanti AC; Niaura R; Rehberg K; Mays D
Tob Regul Sci; 2020 Mar; 6(2):81-90. PubMed ID: 34504901
[TBL] [Abstract][Full Text] [Related]
17. Heated tobacco product (IQOS) induced pulmonary infiltrates.
Thomas M; Hameed M; Alhadad S; Haq IU
Respir Med Case Rep; 2024; 49():102026. PubMed ID: 38712315
[TBL] [Abstract][Full Text] [Related]
18. A scoping review of the toxicity and health impact of IQOS.
Ghazi S; Song MA; El-Hellani A
Tob Induc Dis; 2024; 22():. PubMed ID: 38832049
[TBL] [Abstract][Full Text] [Related]
19. Heated tobacco product IQOS induces unique metabolic signatures in human bronchial epithelial cells.
Curley EO; Abu Aboud O; Chmiel KJ; Nayak AP; Fiehn O; Zeki AA; Sharma P
ERJ Open Res; 2024 Mar; 10(2):. PubMed ID: 38444658
[No Abstract] [Full Text] [Related]
20. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.
McKelvey K; Baiocchi M; Halpern-Felsher B
Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
